Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tissium

Explore full profile

Develops biodegradable sealants and adhesives for wound closure in the field of minimally-invasive surgery

Paris, FranceFounded 2013Biotech & Life Sciences
Valuation $250–500M Last recorded · 2026
Revenue $10–50M Latest reported FY
Headcount 100–500 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Tissium and the history behind them.

About Tissium

Tissium is a startup operating in the medical technology sector, specifically in the development and production of biopolymers. These biopolymers are designed to repair and reconstruct tissue in the human body. The company's innovative technology is based on the storage and access of technical data, which is used to improve the functionality and effectiveness of their products.

Tissium's primary clients are healthcare providers, including hospitals and clinics, who use their products for surgical procedures. The company operates in the global healthcare market, which is continually growing due to the increasing demand for advanced medical solutions.

The business model of Tissium is based on the development, production, and sale of their biopolymers. They invest heavily in research and development to create innovative products that meet the needs of their clients. Once these products are developed, they are sold to healthcare providers. The company generates revenue from the sale of these products.

Tissium also uses technical storage and access for statistical purposes. This data is used to track the performance of their products and to make improvements where necessary. However, the company ensures that this data is used responsibly and cannot be used to identify individuals without a subpoena or voluntary compliance from an Internet Service Provider.

In summary, Tissium is a medical technology startup that develops and sells biopolymers for tissue repair and reconstruction. They use technical data to improve their products and operate in the global healthcare market, serving healthcare providers.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2013
Headquarters
Paris, France
Employees
146
Open positions
15
Dealroom signal
85.4/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotech & Life Sciences, Biotechnology, Biomedical, Surgery, Tissue Engineering, Biodegradable, Biopolymers, Non-Invasive medical devices and treatments
Technology
Hardware, Deep Tech
Business model
Manufacturing
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
DEBTDebt Jun 2026 $33M — European Investment Bank ↗
SERIES DOther financing Jun 2026 $33M $275M Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Tissium website traffic

Latest recorded traffic for Tissium is 3.9K monthly website visits, up 5.4% over the last three months. Tissium's team grew 5% over the past year.

Latest monthly visits3.9K 3-month web change+5.4% 1-year team growth+5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Investments for the Future (PIA)

Series A11 investors entered at this stage

  • Omnes Capital
  • Bpifrance
  • Crédit Mutuel Equity
  • Sofinnova Partners
  • Karista
  • M I INVESTMENT HOLDING LIMITED
  • European Investment Fund
  • M&L Group
  • Valquest Partners
  • Crédit Mutuel Innovation
  • BNP Paribas Développement

Series B and later6 investors entered at this stage

  • BNP Paribas
  • Cathay Capital
  • ISALT Gestion
  • Mérieux Equity Partners
  • Cathay Health
  • European Investment Bank

Other known investors1 additional known investor

  • Massachusetts Institute of Technology
Team profiled 15 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇫🇷 France78.1%
🇺🇸 United States17.5%
🇧🇪 Belgium2.6%
🇮🇱 Israel0.9%
🇹🇷 Turkey0.9%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tissium on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tissium’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.